Aker BioMarine signs first pharmaceutical agreement for development of therapies based on LYSOVETA™

Aker BioMarine签署了第一份基于Lysoveta™的治疗药物开发协议

2021-01-14 13:03:02 BioSpace

本文共1807个字,阅读需5分钟

Aker BioMarine has entered into an agreement with serial biotech entrepreneur Dr. Michael Davidson and his wholly owned company Medical Food Solutions Research, to develop pharmaceutical therapies for brain and eye health based on Aker BioMarine’s product LYSOVETA, LPC bound EPA/DHA. This is the first commercial pharmaceutical agreement Aker BioMarine is entering for its new LYSOVETA business area.   Under the terms of the agreement: A new company will be established to develop the therapies. Aker BioMarine will receive 50 percent of the shares in this company. A new company will be established to develop the therapies. Aker BioMarine will receive 50 percent of the shares in this company. Aker BioMarine will grant an exclusive licence under its IP to the company. The scope of such licence is limited to the distinct products and therapies to be developed by the company. In exchange for such an exclusive licence, Aker BioMarine will receive milestone payments and double-digit royalties from commercial sales of the therapies. Aker BioMarine will grant an exclusive licence under its IP to the company. The scope of such licence is limited to the distinct products and therapies to be developed by the company. In exchange for such an exclusive licence, Aker BioMarine will receive milestone payments and double-digit royalties from commercial sales of the therapies. Aker BioMarine will supply the company with all its LPC product needs. Aker BioMarine will supply the company with all its LPC product needs. The company will seek to raise approximately 30M USD from external investors to fund early clinical trials to obtain proof of concept for the therapies. The company will seek to raise approximately 30M USD from external investors to fund early clinical trials to obtain proof of concept for the therapies.   The company established will seek to develop therapies for treatment for the following indications:   Diseases related to brain function and development: Alzheimer’s Disease, AD – ApoE4 related AD, which stands for 35 percent of all AD cases. Gestational diabetes – associated with lower uptake of DHA in the fetus and might cause abnormalities in the development of the brain.   Diseases related to eye health and vision: Dry age-related macular degeneration – age related vision decline. Dry eye syndrome – low quality or low production of tears causing inflammation and blurred vision. Stargardt’s juvenile blindness – inherited eye disease that may cause vision loss from early age.   “These are all diseases where there is no effective method of treatment available today, and which are having big impact on the life quality of those affected,” says Dr. Michael Davidson. “By using the breakthrough discovery of LPC showing how EPA/DHA can effectively be delivered to the brain and eyes combined with the knowledge of EPA/DHA’s role in these diseases, gives us great confidence in the opportunities that lie within the use of LYSOVETA for development of treatments towards these diseases.”   “This collaboration merges Dr. Davidson’s experience and track record from successful drug developments with Aker BioMarine’s IP and unique position for production and processing of LPC-EPA/DHA, and creates a strong basis for the development of new products within the pharmaceutical sphere,” says Matts Johansen, CEO, Aker BioMarine. “The agreement with Dr. Davidson is an important step to position Aker BioMarine as a global leader in development and commercialization in the LPC space.”   Dr. Michael Davidson, Clinical Professor of Medicine and Director of the Lipid Clinic at the University of Illinois Chicago, has a track record of founding and developing successful pharmaceutical companies. He was the founder of Omthera which was acquired by AstraZeneca in 2013 for 443M USD, and later founded Corvidia Therapeutics which was acquired by NovoNordisk for 2.1B USD in 2020. He is a leading expert in Lipidology. He has broad experience with the use of lipids for therapeutical purposes and has conducted more than 1000 clinical trials.   In November 2020, Aker BioMarine announced the new segment LYSOVETA, with IP and capabilities for production of commercial volumes of LPC-bound EPA/DHA from krill. Aker BioMarine will continue to seek partnerships within the pharmaceutical space to develop other therapies based on science in the field of LPC and the ability LYSOVETA has for targeted delivery of EPA and DHA.    For further information, please contact: Katrin Berntsen, Director Communication  Mobile: +47 92 05 45 70 Email: katrin.berntsen@akerbiomarine.com   Lisa Miller, Communications Director, US Email: Lisa.miller@akerbiomarine.com   About Aker BioMarine   Aker BioMarine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. The company develops krill-based ingredients for nutraceutical, aquaculture, and animal feed applications. The company’s fully transparent value chain stretches from sustainable krill harvesting in pristine Antarctic waters through its Montevideo logistics hub, Houston production plant, and all the way to customers around the world.
阿克生物制药公司与连续的生物技术企业家Michael Davidson博士和他的全资公司Medical Food Solutions Research达成协议,以阿克生物制药公司的产品LYSOVETA,LPC bound epa/dha为基础,开发用于大脑和眼睛健康的药物疗法。这是阿克生物制药公司为其新的LYSOVETA业务领域签署的第一份商业制药协议。 根据协议条款: 将成立一家新公司来开发这种疗法。阿克生物制药公司将获得该公司50%的股份。 将成立一家新公司来开发这种疗法。阿克生物制药公司将获得该公司50%的股份。 Aker BioMarine将向该公司授予其知识产权下的独占许可。该许可的范围仅限于公司将开发的不同产品和疗法。作为这样一个独家许可的交换条件,阿克生物医药公司将从这些疗法的商业销售中获得里程碑式的付款和双位数的版税。 Aker BioMarine将向该公司授予其知识产权下的独占许可。该许可的范围仅限于公司将开发的不同产品和疗法。作为这样一个独家许可的交换条件,阿克生物医药公司将从这些疗法的商业销售中获得里程碑式的付款和双位数的版税。 阿克生物制药公司将向该公司提供其所有的LPC产品需求。 阿克生物制药公司将向该公司提供其所有的LPC产品需求。 该公司将寻求从外部投资者那里筹集大约3000万美元,用于资助早期临床试验,以获得该疗法的概念验证。 该公司将寻求从外部投资者那里筹集大约3000万美元,用于资助早期临床试验,以获得该疗法的概念验证。 成立的公司将寻求开发治疗下列适应症的疗法: 与脑功能和发育有关的疾病; 阿尔兹海默病,AD与ApoE4相关的AD,占所有AD病例的35%。 妊娠期糖尿病与胎儿对DHA的摄取降低有关,并可能导致大脑发育异常。 与眼健康和视力有关的疾病: 干性老年性黄斑变性老年性视力下降。 干眼症泪液质量低或产量低,引起炎症和视力模糊。 Stargardts的青少年失明遗传的眼病,可能导致视力从幼年开始下降。 迈克尔戴维森博士说,这些都是目前还没有有效治疗方法的疾病,这些疾病对患者的生活质量产生了很大影响。LPC的突破性发现表明Epa/DHA如何有效地传递到大脑和眼睛,结合Epa/DHA在这些疾病中的作用的知识,使我们对使用LYSOVETA开发这些疾病治疗的机会充满信心。 Aker biomarine CEO Matts Johansen说,这一合作将davidsons博士的成功药物开发经验和记录与Aker biomarines在lpc-epa/dha生产和加工方面的IP和独特地位结合起来,为制药领域的新产品开发奠定了坚实的基础。与戴维森博士的协议是将阿克生物制药公司定位为LPC领域开发和商业化的全球领导者的重要一步。 Michael Davidson博士是伊利诺伊大学芝加哥分校的临床医学教授和脂质诊所主任,他在创办和发展成功的制药公司方面有着良好的记录。他是2013年被阿斯利康以4.43亿美元收购的Omthera公司的创始人,后来又创立了Corvidia Therapeutics,并于2020年被NovoNordisk以21亿美元收购。他是脂质学的权威专家。他在使用脂类进行治疗方面有丰富的经验,并进行了1000多项临床试验。 2020年11月,Aker BioMarine宣布了新的分部LYSOVETA,该分部具有从磷虾生产与LPC结合的EPA/DHA的能力。Aker BioMarine将继续在制药领域寻求合作伙伴,以开发基于LPC领域科学和LYSOVETA有针对性地提供EPA和DHA的能力的其他疗法。 如需进一步信息,请联系: Katrin Berntsen,传播总监 手机:+47 92 05 45 70 电子邮件:katrin.berntsen@akerbiomarine.com Lisa Miller,美国通讯总监 电子邮件:lisa.miller@akerbiomarine.com 关于Aker BioMarine AkerBiomarine是一家生物技术创新者和南极磷虾采集公司,致力于改善人类和地球的健康。该公司为营养品,水产养殖和动物饲料应用开发磷虾为基础的配料。该公司完全透明的价值链从南极原始水域的可持续磷虾捕捞到蒙得维的亚物流中心,休斯敦生产厂,一直延伸到世界各地的客户。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文